Most systems marketed as pharmacovigilance software can log a case and store it somewhere searchable. Far fewer can validate that case against hundreds of E2B(R3) rules in real time, catch a MedDRA coding inconsistency before it reaches submission, or show on demand why a case was scored as complete before it went out the gateway. That gap between "stores cases" and "actively reduces case-level risk" is where a lot of platform evaluations go wrong.
Here are seven specific capabilities worth evaluating closely before trusting a platform with pharmacovigilance case review.
A platform should validate case data as it's entered, not just before final submission. Field-level checks against ICH E2B(R3), regional gateway requirements like EMA EVWEB and FDA ESG, and current business rules catch errors at the point of entry when they're cheapest and fastest to fix rather than after a case has already moved downstream.
Coding consistency depends on pulling terms from the current MedDRA database structure, not generating plausible-sounding codes from pattern matching. A platform worth trusting should map the full hierarchy directly from the database and fall back to historical coding decisions for similar verbatim text and should never save a code without human confirmation.
Not every case carries the same completeness or quality risk, but many platforms still simply move cases through a queue without any consistent quality signal attached. A completeness and quality score assigned before submission not discovered afterward through a query is what actually differentiates proactive quality management from reactive fixing.
21 CFR Part 11 expects e-signature workflows and a continuous, immutable audit trail for safety records. This needs to be a default behavior of the system, not a configuration a team has to remember to turn on for every study.
When a case comes back with a query or rejection, most systems help resolve that individual instance. Fewer platforms make it easy to see whether the same root cause is quietly repeating across other cases — which is the difference between fixing symptoms and catching a systemic pattern early.
A platform that only handles one region's rule set forces teams to juggle separate tools as studies expand internationally. Broad, current coverage across major regulatory frameworks not just the most common one reduces the operational overhead of running multi-region safety programs.
Safety-relevant literature signals shouldn't require a completely separate workflow from case management. A platform that can rank literature relevance and turn a selected article into a draft, review-ready case rather than requiring manual re-entry closes a gap that otherwise sits between medical affairs and safety teams.
| Capability | Basic Case Tracker | Genuine Safety Platform |
|---|---|---|
| Validation timing | Checked before final submission | Checked in real time, field by field |
| MedDRA coding | Free-text or manual lookup | Pulled from the actual database hierarchy |
| Case quality | Same treatment for every case | Scored before submission |
| Audit trail | Optional or manually maintained | Immutable and continuous by default |
| Root-cause tracking | Case-by-case fixes | Pattern visibility across cases |
| Regulatory coverage | Single region | Broad, current multi-region rule sets |
| Literature surveillance | Separate manual process | Connected to case creation |
Pharmacovigilance obligations aren't just about submitting a case on time they're about demonstrating that the same standard was applied consistently, case after case, across an entire safety program. An inspector reviewing case handling is checking for consistency and defensibility, not just individual compliance. A platform that only stores and routes cases, without validating, scoring, and tracking patterns across them, leaves that consistency dependent entirely on manual reviewer discipline rather than the system itself.
Cloudbyz's pharmacovigilance tools are built around these seven capabilities directly. AI VigiCheck runs real-time, field-level E2B(R3) validation covering over 200 rules spanning ICH E2B(R3), EMA EVWEB, and FDA ESG, and assigns a completeness and quality score to each case before gateway submission. The Medical Coding Assistant pulls the full MedDRA hierarchy directly from the database rather than generating codes, falls back to historical decisions and fuzzy search for similar cases, and only ever saves a final code on human confirmation. Evidence IQ connects literature surveillance directly to case creation, ranking relevance and turning selected findings into a review-ready draft rather than a separate manual research step. Across all of these, e-signature workflows and immutable audit trails are built in by default, not configured separately per study.
The right question isn't which platform has the longest feature list it's which one actually reduces case-level risk at the point where risk is created, rather than simply organizing that risk into a searchable queue.
Book a demo with Cloudbyz.